IPO Report: Lumenis (LMNS)

Francis Gaskins  |

Lumenis (LMNS) provides energy-based, minimally invasive clinical solutions primarily for the aging population.

One other company is scheduled for the week of February 24, 2014. The full IPO calendar is available at IPOpremium.

LMNS’s manager and joint managers are Goldman Sachs, Credit Suisse, and  Jefferies.  The co-Manager is Wells Fargo Securities.

LMNS scheduled a $100 million IPO with a market capitalization of $564 million at a price range midpoint of $16 for Thursday, February 27, 2014, on the Nasdaq


LMNS has established a strong brand across diverse end-markets, consisting of its surgical, ophthalmic and aesthetic segments.

Some income statement metrics include


·        2013 revenue was up 6.4% verus 2012 to $265 million. 

·        Gross profit was 54% and increased 15.4% to $142 million. 

·        Operating income increased 175% to $26 million. 

·        After tax income increased $149% to $17 million, but the tax rate was only 14%.


LMNS believes that its focus on product development has resulted in its strongest pipeline of new products and applications in over a decade.




Valuation Ratios


Price /

Price /

Price /

Price /

% offered


Cap (mm)





in IPO

Lumenis Ltd. (LMNS)
















LMNS is an Israeli-based global company sponsored by Goldman.  Most Isaeli-based global companies have done well in the IPO market.

Subscribe to get our Daily Fix delivered to you inbox 5 days a week

LMNS’s P/E ratio is a reasonable 32, and the new product pipeline is the strongest in over a decade.

The IPO rating on LMNS is a buy.

SEC Filings


LMNS is a leading global, highly diversified and growing provider of innovative energy-based, minimally invasive clinical solutions primarily for the aging population.

It has established a strong brand and leadership position across diverse end-markets, consisting of its surgical, ophthalmic and aesthetic segments, and its products are utilized for both medically necessary and elective procedures.

LMNS focused product offerings include solutions for a wide range of minimally invasive procedures across those segments.

Product pipeline

LMNS’ focus on product development has resulted in its strongest pipeline of new products and applications in over a decade.

Specifically, LMNS expects to launch one to two new product platforms in each of its three segments by the end of 2014.

Target markets

The principal target markets for LMNS’ products are hospitals, outpatient clinics, ambulatory surgery centers, physicians’ offices, private clinics and aesthetic chains.

Sales & Marketing

LMNS markets, sells and services its products primarily through its direct sales and service organization, which provides it with a strong presence in its key markets, including the United States, China, Japan, India, Germany and Australia, which generated 70% of its revenues for the year ended December 31, 2013.

LMNS sells to the remainder of its geographies through an extensive global distributor network, consisting of over 170 independent distributors in over 70 countries worldwide.

LMNS’ service organization of over 200 people supports the growth of its global customer base and provides it with an attractive recurring revenue stream.

LMNS believes it is well-positioned to capitalize on the large and growing emerging markets opportunity, specifically the APAC region, where China represents LMNS’ second largest individual market globally (after the United States) and which LMNS believes will be an important driver of its future growth.

LMNS generated $86.1 million in revenues in the APAC region for the year ended December 31, 2013, representing 14.9% year-over-year growth and 32.5% of LMNS’ total revenues for that period.

Dividend Policy

No dividends planned

Intellectual Property
LMNS holds more than 140 patents in the United States and an additional 85 patents throughout the rest of the world and has outstanding applications for 32 patents in the United States and 40 patents outside of the United States as of December 31, 2013.

LMNS believes that its patent portfolio alone may not provide a significant advantage over our competitors and therefore, the competitive advantage depends on LMNS’s ability to leverage its  current brand strength and existing market position


Competition arises from laser and other light-based products, as well as from other treatment modalities and alternate technologies that are not based upon laser or light-based technologies.

LMNS also faces competition from companies selling accessories to, and offering services for, its products, as well as companies selling devices, particularly in the aesthetic market, for home use. Competitors range in size from small, single product companies to large, multinational corporations, which may have greater resources than LMNS.

LMNS’ principal direct competitors consist of the following companies:

Surgical — American Medical Systems; Deka Laser Technologies; Dornier MedTech America; Karl Storz; Lisa Laser Products and OmniGuide.

Ophthalmic —  Carl Zeiss Meditec; Ellex; Iridex; Nidek and Quantel Medical.

Aesthetic — Alma Lasers; Cutera; Cynosure; Solta Medical and Syneron.

5% stockholders

Viola-LM Partners L.P. and affiliates  45.9%

XT Hi-Tech Investments (1992) Ltd. and affiliates 31.4%

Bank Hapoalim B.M.  5.2%

Harel Beit-On    46.3%

Use of proceeds

LMNS expects to net $90.2 million from its IPO. Proceeds are allocated as follows:

operations and for other general corporate purposes, including but not limited to working capital requirements, capital expenditures, investments, research and development, product development and sales and marketing expenditures.

LMNS may also use a portion of the net proceeds for the potential acquisition of, or investment in, technologies, products or companies that complement its business, although LMNS has no understandings, commitments or agreements to consummate any such acquisition or investment.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.


Symbol Last Price Change % Change